DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
Cancer Cell, ISSN: 1535-6108, Vol: 17, Issue: 3, Page: 235-248
2010
- 175Citations
- 224Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations175
- Citation Indexes173
- 173
- CrossRef130
- Clinical Citations1
- PubMed Guidelines1
- Policy Citations1
- Policy Citation1
- Captures224
- Readers224
- 224
Article Description
Synthetic sickness/lethality (SSL) can be exploited to develop therapeutic strategies for cancer. Deficiencies in the tumor suppressor proteins MLH1 and MSH2 have been implicated in cancer. Here we demonstrate that deficiency in MSH2 is SSL with inhibition of the DNA polymerase POLB, whereas deficiency in MLH1 is SSL with DNA polymerase POLG inhibition. Both SSLs led to the accumulation of 8-oxoG oxidative DNA lesions. MSH2/POLB SSL caused nuclear 8-oxoG accumulation, whereas MLH1/POLG SSL led to a rise in mitochondrial 8-oxoG levels. Both SSLs were rescued by silencing the adenine glycosylase MUTYH, suggesting that lethality could be caused by the formation of lethal DNA breaks upon 8-oxoG accumulation. These data suggest targeted, mechanism-based therapeutic approaches.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1535610810000371; http://dx.doi.org/10.1016/j.ccr.2009.12.046; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77649311945&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/20227038; https://facultyopinions.com/prime/2707957#eval2602059; http://dx.doi.org/10.3410/f.2707957.2602059; https://linkinghub.elsevier.com/retrieve/pii/S1535610810000371; https://facultyopinions.com/prime/2707957#eval2371055; http://dx.doi.org/10.3410/f.2707957.2371055; http://www.cell.com/cancer-cell/abstract/S1535-6108(10)00037-1; http://f1000.com/2707957#eval2371055; http://f1000.com/2707957#eval2602059; http://linkinghub.elsevier.com/retrieve/pii/S1535610810000371; http://europepmc.org/abstract/med/20227038; http://europepmc.org/articles/PMC2845806; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.cell.com%2Fcancer-cell%2Fabstract%2FS1535-6108%2810%2900037-1&rc=0&code=cell-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.cell.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253DaaaEbLbuCkVpX8XIV33xv%2526MAID%253DMyOsJcXrOsOly6Z7pl91Rg%25253D%25253D%2526SERVER%253DWZ6myaEXBLFhx%25252B6Ws3Nrug%25253D%25253D%2526ORIGIN%253D424372823%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.cell.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253DaaaEbLbuCkVpX8XIV33xv%2526MAID%253DMyOsJcXrOsOly6Z7pl91Rg%25253D%25253D%2526SERVER%253DWZ6myaEXBLFhx%25252B6Ws3Nrug%25253D%25253D%2526ORIGIN%253D424372823%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.cell.com%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3DaaaEbLbuCkVpX8XIV33xv%26MAID%3DMyOsJcXrOsOly6Z7pl91Rg%253D%253D%26SERVER%3DWZ6myaEXBLFhx%252B6Ws3Nrug%253D%253D%26ORIGIN%3D424372823%26RD%3DRD&acw=&utt=
Faculty Opinions Ltd
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know